Review article · 2025 · Open access

Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years

Jian Wan, Jiaming Zhou, Zhuo Wang, Dan Liu, Hao Zhang, Shengmao Xie, Kaichun Wu

Chinese Medical Journal, 138(7), 763–776 · Published 25 February 2025 · DOI 10.1097/cm9.0000000000003542

Open full textCite this paper

In brief

“Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years” is a 2025 review article by Jian Wan and 6 co-authors, published in Chinese Medical Journal. OpenAlex counts 114 citations as of 22 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Chinese Medical Journal.

Citations
114
Most cited in
2026 (91)
Field-weighted impact
14.06
References
106
Authors
7

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a chronic inflammation of the gastrointestinal tract with unknown etiology. The cause of IBD is widely considered multifactorial, with prevailing hypotheses suggesting that the microbiome and various environmental factors contribute to inappropriate activation of the mucosal immune system in genetically susceptible individuals. Although the incidence of IBD has stabilized in Western countries, it is rapidly increasing in newly industrialized countries, particularly China, making IBD a global disease. Significant changes in multiple biomarkers before IBD diagnosis during the preclinical phase provide opportunities for earlier diagnosis and intervention. Advances in technology have driven the development of telemonitoring tools, such as home-testing kits for fecal calprotectin, serum cytokines, and therapeutic drug concentrations, as well as wearable devices for testing sweat cytokines and heart rate variability. These tools enable real-time disease activity assessment and timely treatment strategy adjustments. A wide range of novel drugs for IBD, including interleukin-23 inhibitors (mirikizumab, risankizumab, and guselkumab) and small-molecule drugs (etrasimod and upadacitinib), have been introduced in the past few years. Despite these advancements, approximately one-third of patients remain primary non-responders to the initial treatment, and half eventually lose response over time. Precision medicine integrating multi-omics data, advanced combination therapy, and complementary approaches, including stem cell transplantation, psychological therapies, neuromodulation, and gut microbiome modulation therapy, may offer solutions to break through the therapeutic ceiling.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wan, J., Zhou, J., Wang, Z., Liu, D., Zhang, H., Xie, S., & Wu, K. (2025). Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years. Chinese Medical Journal, 138(7), 763–776. https://doi.org/10.1097/cm9.0000000000003542

MLA 9

Wan, Jian, et al. “Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years.” Chinese Medical Journal, vol. 138, no. 7, 2025, pp. 763–776. https://doi.org/10.1097/cm9.0000000000003542.

Chicago

Wan, Jian, Jiaming Zhou, Zhuo Wang, Dan Liu, Hao Zhang, Shengmao Xie, and Kaichun Wu. 2025. “Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years.” Chinese Medical Journal 138 (7): 763–776. https://doi.org/10.1097/cm9.0000000000003542.

Harvard

Wan, J. et al. (2025) ‘Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years’, Chinese Medical Journal, 138(7), pp. 763–776. doi:10.1097/cm9.0000000000003542.

IEEE

J. Wan et al., “Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years,” Chinese Medical Journal, vol. 138, no. 7, pp. 763–776, 2025, doi: 10.1097/cm9.0000000000003542.

BibTeX

@article{wan2025epidemiology,
  title     = {{Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years}},
  author    = {Wan, Jian and Zhou, Jiaming and Wang, Zhuo and Liu, Dan and Zhang, Hao and Xie, Shengmao and Wu, Kaichun},
  journal   = {Chinese Medical Journal},
  year      = {2025},
  volume    = {138},
  number    = {7},
  pages     = {763--776},
  doi       = {10.1097/cm9.0000000000003542},
  url       = {https://doi.org/10.1097/cm9.0000000000003542}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease

  • inflammatory bowel disease
  • ulcerative colitis
  • Crohn's disease
  • gut microbiota
  • mucosal immune activation
  • IBD incidence
  • biomarkers
  • preclinical stage

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Wan, J., Zhou, J., Wang, Z., Liu, D., Zhang, H., Xie, S., & Wu, K. (2025). Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years. Chinese Medical Journal, 138(7), 763–776. https://doi.org/10.1097/cm9.0000000000003542

How many times has this paper been cited?

114 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Chinese Medical Journal: sign in and open the full text from this page.

Who wrote this paper?

Jian Wan, Jiaming Zhou, Zhuo Wang, Dan Liu, Hao Zhang, Shengmao Xie, Kaichun Wu.

What is the DOI of this paper?

10.1097/cm9.0000000000003542, permanently at https://doi.org/10.1097/cm9.0000000000003542. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.